[Massive myocardial hypertrophy in hypertrophic cardiomyopathy: a risk factor for sudden death and high defibrillation threshold during cardioverter-defibrillator implantation].
暂无分享,去创建一个
[1] G. Boriani,et al. Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? , 2004, Circulation.
[2] C. Tracy,et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.
[3] M. Link,et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. , 2003, Circulation.
[4] B. Maron,et al. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. , 2003, The American journal of cardiology.
[5] V. Jayam,et al. High Defibrillation Thresholds in Transvenous Biphasic Implantable Defibrillators: , 2003, Pacing and clinical electrophysiology : PACE.
[6] R. Kerber,et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices , 2002 .
[7] R. Kerber,et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). , 2002, Circulation.
[8] G. Boriani,et al. Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverter-defibrillator implant. , 2002, International Journal of Cardiology.
[9] M. Gold,et al. Clinical Predictors of Defibrillation Thresholds with an Active Pectoral Pulse Generator Lead System , 2002, Pacing and clinical electrophysiology : PACE.
[10] Thomas D. Nielsen,et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. , 2001, The American journal of cardiology.
[11] P. Elliott,et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.
[12] P. Elliott,et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.
[13] G. Boriani,et al. High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol. , 2000, Heart & lung : the journal of critical care.
[14] F. Morady,et al. Effect of Chronic Amiodarone Therapy on Defibrillation Energy Requirements in Humans , 2000, Journal of cardiovascular electrophysiology.
[15] B. Maron,et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[16] M. Link,et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[17] R. Peters,et al. Clinical predictors of transvenous defibrillation energy requirements. , 1997, The American journal of cardiology.
[18] P. Dorian,et al. d‐Sotalol Decreases Defibrillation Energy Requirements in Humans: , 1996, Journal of cardiovascular electrophysiology.
[19] F. Marchlinski,et al. Early Postoperative Rise in Defibrillation Threshold in Patients with Nonthoracotomy Defibrillation Lead Systems: , 1996, Journal of cardiovascular electrophysiology.